Adherium Ltd has released a press release.
AstraZeneca selected Adherium Smartinhaler for its study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Adherium
- Non-Renounceable Rights Issue Offer Completes
- Placement and Entitlement Offer to raise up to $8.37 million
- First Patient Enrolled in Major e-health Clinical Study
- Adherium receives $1.5m Australian R&D Tax Rebate
- New CEO Appointed - Dr Paul Mastoridis
Later from Adherium
- Management Change
- Adherium Secures $2.6M to Advance Smart Inhaler in US
- $900K Capital Raise to Accelerate Smart Inhaler in US
- Accel Non-Renounceable Entitlement Offer to raise up to $4m
- Prospectus
Follow Adherium into a list and get an email when it puts out news.
Follow Adherium